share_log

方盛制药(603998.SH):参与投资设立的并购基金合伙人合伙份额发生变动

Hunan Fangsheng Pharmaceutical (603998.SH): Changes occurred in the partnership shares of the merger and acquisition Fund established through investments.

Gelonghui Finance ·  Dec 16 04:40

On December 16, Gelonghui reported that Hunan Fangsheng Pharmaceutical (603998.SH) announced that on December 13, 2024, the company received a "Notice Letter" from Zhuhai Hengqin Zhongke Jian Chuang Investment Partnership (Limited Partnership) (referred to as "Zhongke Jian Chuang"). Zhongke Jian Chuang agreed to let Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (referred to as "Maipu Technology") subscribe for its additional 26.49 million yuan partnership shares for 30 million yuan, and the company waived its right of first refusal. This change in partnership shares does not harm the company's interests, and the number of partnership shares held by the company has not changed (the proportion of partnership shares decreased from 7.43% to 5.88%), which will not lead to a change in the scope of the company's consolidated financial statements and will not have a direct impact on the company.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment